A r t i c l e s DLBCL, the most common lymphoid malignancy in adulthood, is considered a curable disease in only ~50% of cases 1,2 . This incomplete success indicates the need for further studies aimed at elucidating its pathogenesis through the identification of genes and cellular pathways that are structurally altered in this disease and which may represent targets for new therapeutic approaches.
A r t i c l e s DLBCL, the most common lymphoid malignancy in adulthood, is considered a curable disease in only ~50% of cases 1, 2 . This incomplete success indicates the need for further studies aimed at elucidating its pathogenesis through the identification of genes and cellular pathways that are structurally altered in this disease and which may represent targets for new therapeutic approaches.
Current understanding of the biology of DLBCL indicates the existence of several disease subgroups reflecting the derivation from B cells at discrete stages of differentiation, namely germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL and primary mediastinal B-cell lymphoma (PMBCL) [3] [4] [5] . These subtypes are associated in part with distinct genetic lesions, indicating the involvement of separate oncogenic pathways 6, 7 . In particular, chromosomal translocations involving the BCL2 and MYC oncogenes and mutations of the EZH2 methyltransferase are almost exclusively observed in GCB DLBCL [7] [8] [9] , whereas the less curable ABC DLBCL is preferentially associated with structural alterations disrupting terminal B-cell differentiation (PRDM1 inactivation) [10] [11] [12] and with a variety of lesions that result in the constitutive activation of the NF-κB transcription complex (most commonly, mutations of TNFAIP3, CARD11, CD79B and MYD88) [13] [14] [15] [16] . More recently, chromosomal translocations involving CIITA and amplifications or rearrangements of the genes encoding for the CD274 (also known as PDL1) and CD273 (also known as PDL2) ligands have been reported as recurrent events in PMBCL [17] [18] [19] . Additional lesions are common to GCB and ABC DLBCL, including BCL6 translocations 20 and inactivation of the acetyltransferase genes CREBBP and EP300 (ref. 21) . Overall, these alterations only affect a fraction of DLBCL cases, whereas the full spectrum of genomic lesions that contribute to malignant transformation remains unknown.
Major improvements in sequencing technologies have now provided an unprecedented opportunity to examine the cancer genome for large-scale identification of genomic alterations in a comprehensive and unbiased manner. The present study was aimed at expanding our current knowledge of the number and type of genetic alterations that are present in the DLBCL coding genome by integrating massively parallel whole-exome sequencing (WES) and genome-wide high-density SNP array analysis. This combined approach allowed the definition of the degree of complexity characterizing the DLBCL coding genome and revealed the involvement of several previously unrecognized dysregulated genes and pathways.
RESULTS

Mutational load by exome sequencing analysis
In order to determine the load of somatic, non-silent mutations that are clonally represented in the DLBCL genome, we performed massively parallel sequencing of paired tumor and normal DNA from six untreated individuals with de novo DLBCL (three with ABC, one with A r t i c l e s GCB, one with non-GCB and one with unclassified (NC) DLBCL; Supplementary Table 1 ) by using a hybridization-capture method for the enrichment of non-repetitive protein-coding genes (~85% of the NCBI Consensus Coding Sequence (CCDS) database) followed by next-generation sequencing using the 454 Genome Sequencer FLX instrument (Supplementary Fig. 1 ). We also analyzed by direct sequencing the coding exons of selected genes that have been previously implicated in other hematologic and non-hematologic cancers but which are not represented in the capture array (for example, NOTCH1, MLL2 and CYLD) [22] [23] [24] [25] [26] [27] . The WES approach produced 11.8 billion bp of mapped sequences (~2,3 million reads per case of average length 305 bp) with a mean depth of 9.8× (range 8.9× to 12.8× per case) and, on average, 77.7% of the target sequence being covered by at least five reads (range 70.8-81.4%) (Supplementary Table 2 ). This level of resolution allowed us to provide an initial estimate of the order of magnitude of the mutation load in the disease and to identify genes that are relevant to its pathogenesis because they are recurrently mutated across different disease subtypes (with a 70% probability of detecting mutations in genes that are affected at ~30% prevalence) (Online Methods and Supplementary Note).
Sanger-based resequencing of candidate variants in the matched tumor and normal DNA validated the presence of 96 somatic, non-silent mutations involving 93 distinct genes (Supplementary Tables 3,4 ). This analysis also confirmed that the sequence variants were present in a major clone, as indicated by the clear signal in the chromatogram. The mutation load per case varied markedly across samples (mean 16, range 5-29) (Fig. 1a) . Mutations were largely represented by single nucleotide substitutions leading to amino acid changes (n = 78; 82.2%) but also included in-frame insertions or deletions (n = 3), nonsense mutations (n = 4), alterations in canonical splice sites (n = 7) and frameshift deletions of short nucleotide stretches (n = 4), collectively accounting for ~16% of the events (Fig.1b and Supplementary Table 3) . Analogous to the spectrum reported in other cancer types 26, 28 , we observed a predominance of transitions over transversions (n = 58:30, ratio of 1.9) and a preferential targeting of G and C nucleotides (71.6% affecting G/C compared to 28.4% affecting A/T nucleotides; after correction for target exome sequence composition, P = 0.004) (Fig. 1c) ; moreover, there was a significant bias toward alterations at 5′-CpG-3′ dinucleotides, which account for 10% of all non-synonymous changes (the frequency of CpG nucleotides in the target exome is ~3%; P < 0.0001) (Fig. 1d) Table 3) . Although the functional consequences of the mutations found in these 87 genes are largely unknown, 71 of them (81.6%) are expected to alter the function of the encoded protein based on at least one of two distinct prediction algorithms (Supplementary Table 3 ).
Copy number analysis
We then analyzed the same six DLBCL samples (and paired normal DNAs) for the presence of copy number changes by using the Affymetrix SNP6.0 platform, which interrogates ~1.8 million markers, including SNPs and copy number probes. This analysis identified 90 somatically acquired genomic alterations (66 deletions and 24 gains) with considerable variability across individual samples (range 1-31) ( Fig. 2 and Supplementary Table 5 ). Chromosomes 1, 2, 3 and 6q comprised the highest number of lesions, which is in agreement with previous studies that used chromosomal and array-based comparative genomic hybridization 6, 29 , and ten of the changes (three losses and seven gains) involved whole chromosomes or chromosome arms. The SNP array approach correctly identified two deletions of PRDM1 on chromosome 6q21 (in DLBCL2204 and DLBCL2210) and a deletion of chromosome 17p (DLBCL2204), which had all been previously detected by fluorescence in situ hybridization (FISH) analysis. Additional known DLBCL-associated alterations include a focal homozygous deletion of CDKN2A-CDKN2B and a 6q23.3 deletion spanning the TNFAIP3 tumor suppressor. Of the remaining lesions, nine encompassed single genes that likely represent the target of the aberration (for example, TBL1XR1 and NRXN3) (Supplementary Table 5 ). Overall, the detection of 90 copy number alterations, with over 30-fold differences in total load across the six individuals studied, indicates that the genetic landscape of DLBCL is remarkably heterogeneous and that largely distinct types of genes are affected in different individuals.
Overall complexity of the DLBCL coding genome
The combination of whole-exome sequencing and copy number data from the six index cases, together with FISH analysis for three common chromosomal translocations in lymphoma (in BCL6, BCL2 and MYC), provided an integrated snapshot on the complexity of alterations affecting the DLBCL coding genome. In addition A r t i c l e s to the described mutations and copy number aberrations, chromosomal translocations of BCL6 were present in two cases, whereas we observed no alterations at the MYC and BCL2 loci. Few genes were biallelically inactivated by a combination of truncating mutations and/or deletions, as is typical of tumor suppressor genes (for example, TNFAIP3, PRDM1, CDKN2A-CDKN2B, TMEM30A, CD58 and IGSF3). Notably, the relative representation of point mutations compared to copy number changes varied considerably within individual cases (Fig. 3) . Thus, the overall load of tumor-acquired lesions that are present in the major clone was relatively heterogeneous across the six cases studied (average load 31.5, range 16-49).
Recurrent targets of point mutations and copy number changes
One criterion used to assess the pathogenetic relevance of candidate genetic lesions is to examine their recurrence in the disease, which can involve different modes of alteration, including mutations and copy number changes. To increase our ability to detect relevant tumorassociated genomic alterations across and within different DLBCL subgroups, and to identify additional candidate genes for downstream mutation screening in a larger DLBCL dataset, we first extended the SNP array analysis to 73 DLBCL biopsies representative of the two major DLBCL subtypes. Consistent with the results obtained from the discovery panel, this screening confirmed the high degree of complexity of the DLBCL genome, which had an average of 24 acquired copy number aberrations per case, with great variability across individual samples (range 0-92 aberrations), regardless of their DLBCL subtype. Losses were more common than gains (n = 1108 and n = 765, respectively). We identified a total of 325 minimal common regions (MCR) of aberration measuring <1 Mb in size and encompassing 1-3 genes, which most likely represent relevant selected targets. Of these regions, 241 were commonly deleted, with 154 spanning a single gene, and 84 were gained, including 20 focal high-level amplifications (in total, 474 involved genes). Gene annotation clustering analysis using the DAVID algorithm and the list of 560 genes obtained by combining the WES candidates (n = 93) and the MCR candidates (n = 474, 7 of which are in common between the two groups) revealed a significant enrichment in specific functional categories, including regulation of transcription, lymphocyte activation and/or differentiation, chromatin modification, DNA methylation, and antigen processing and presentation (Supplementary Table 6 ), suggesting that dysregulation of these biological processes plays a central role in DLBCL pathogenesis.
Out of this large array of candidates, we prioritized genes for further analysis based on one or more of the following criteria: (i) mutation frequency in the six discovery genomes; (ii) participation in both point mutations and focal MCRs of aberration; (iii) significance scores, as assessed by two independent statistical approaches for the analysis of copy number data, including GISTIC (which is based on the amplitude and the frequency of occurrence of copy number changes) 30 ( Supplementary Fig. 2 and Supplementary Tables 7,8 ) and ComFocal (a newly developed algorithm based on the size, amplitude and frequency of the copy number aberration) (Supplementary Note and Supplementary Fig. 3) ; and (iv) functional annotation. We also included in the analysis genes that had been previously implicated in DLBCL or in other hematologic malignancies. Based on these criteria, we subjected 56 genes to Sanger-based resequencing of their complete coding exons and consensus splice sites in an independent panel of at least 48 (and up to 105) biopsies representative of the main DLBCL subtypes. Figure 4 shows the prevalence of cases with mutations in each of the 56 genes analyzed. Of these 56 genes, 16 were never found mutated in the 48 'screening' cases (the overall frequency, including the discovery cases, was 1 out of 54, or 1.8%). The remaining 40 genes harbored mutations in at least one additional case, and 30 of the genes (including 14 not previously reported in the disease) were altered in >5% of cases, indicating that our selection criteria effectively enriched the list for recurrent and, thus, presumably relevant targets (see Supplementary  Tables 9,10 and paragraphs below for details on the mutations found). These genes point to the involvement of specific biological programs, as described in the following sections.
Alterations in genes controlling chromatin methylation
A prominent feature of the DLBCL genome was the presence of multiple lesions targeting histone or chromatin modification genes. In addition to the recurrent inactivation of the histone Figure 3 DLBCL harbors a heterogeneous load of numerical and structural genomic aberrations. Shown are the combined loads of genetic lesions that were present in the major tumor clone of the six DLBCL discovery subjects (including point mutations, copy number alterations and chromosomal translocations at three common target loci).
A r t i c l e s In most instances, the mutations were clearly inactivating events represented by nonsense mutations (n = 10), frameshift insertions or deletions (n = 11) and a consensus splice site mutation (Fig. 5a,b and Supplementary Table 10) . As a consequence, the corresponding MLL2 alleles are predicted to generate truncated proteins lacking the entire C-terminal cluster of conserved domains (including the SET domain) or substantial portions of it. Eleven additional missense mutations were distributed along the MLL2 protein, with no apparent clustering ( Fig. 5a and Supplementary Table  10 ). Where available (n = 3 cases), analysis of paired normal DNA confirmed the somatic origin of the mutations, which is strongly suggested for the remaining variants based on their absence in public and our own SNP databases (Online Methods). Although the functional consequences of these amino acid changes will have to be tested experimentally, five of them were located within or in close proximity to the conserved PHD, FYRN and SET domains, which are central to MLL2 protein function. In cell lines, MLL2 mutations were exclusively associated with a GCB DLBCL phenotype, where they accounted for ~50% of samples (n = 7 out of 16 compared to n = 0 out of 7 for the ABC DLBCL phenotype), whereas their distribution in primary biopsies was not significantly different between the two subgroups (GCB DLBCL, 27% and ABC DLBCL, ~20%) (Fig. 5c) . With one exception, MLL2 mutations affected a single allele in all evaluable cases and were not accompanied by deletion of the second allele (Fig. 5d) . This pattern of predominant monoallelic inactivation suggests a role for MLL2 as a haploinsufficient tumor suppressor, mutated in ~23% of primary DLBCLs (or 24.3% when including cell lines) (see Discussion section).
In addition to MLL2, several genes involved in histone methylation were targeted by genomic alterations. Our analysis confirmed the occurrence of EZH2 mutations in 6 out of 107 (5.6%) biopsies and 4 out of 23 cell lines, which were almost exclusively of the GCB DLBCL subtype (n = 9 out of 63, or 14.2%) (Figs. 4 and 6a) ; these variants all target a specific hotspot residue that has been associated with increased H3K27 trimethylation activity 8, 32, 33 . In 11 cases, we identified somatic mutations (n = 4) or deletions (n = 7) of KDM2B, a gene encoding an H3K36 histone demethylase (Fig. 6a and Supplementary  Tables 9,11) . Additionally, individual cases harbored genomic deletions or rearrangements of MLL3 (n = 6), MLL5 (n = 2) and MLL ( Fig. 6b and Supplementary Table 11) . As H3K4 methylation has been linked to other chromatin modifiers, such as HATs and Figure 4 Recurrent mutations in DLBCL. Percentage of DLBCL primary cases harboring mutations in 56 candidate genes after targeted resequencing of an expanded screening dataset. The final number of mutated samples over total samples analyzed (including the six DLBCL discovery cases) is given for each gene; this number includes validated somatic mutations as well as variants that are not reported in any available SNP databases (Online Methods). The somatic origin of the mutations was confirmed by analysis of paired normal DNA in at least one case per gene. Red asterisks denote putative tumor suppressor genes as suggested by the presence of predominantly inactivating mutations (stop codons, frameshift mutations and experimentally validated missense mutations). Green asterisks denote genes where the oncogenic activity of the mutation was functionally proven. Black asterisks indicate genes harboring mutations of unclear pathogenic role but which are predicted to truncate the encoded protein in at least one case. A r t i c l e s chromatin remodelers [34] [35] [36] [37] [38] , we looked at the relationship between genetic lesions affecting MLL2 and CREBBP or EP300, which were recently shown to be monoallelically inactivated in up to 39% of DLBCLs 21 . Although the number of individuals studied did not allow robust statistical analyses, most of our cases showed a mutually exclusive involvement of these genes (Fig. 6c) , suggesting that alterations at these chromatin modifiers may represent alternative mechanisms converging on a common transcriptional program. Together, these data suggest that disruption of histone modification and/or chromatin remodeling genes plays a central role in DLBCL pathogenesis (Fig. 6d) .
Mutations of genes controlling immune recognition by T cells
A second set of lesions recurrently observed in DLBCL involves immune-recognition and antigen-presenting functions. Expanding on previous observations from isolated cases, we found frequent inactivating mutations and deletions in B2M, the β2-microglobulin gene. B2M encodes a polypeptide found in association with the major histocompatibility complex class I on the surface of nearly all nucleated cells 39 . In 16 samples (13 out of 111 biopsies and 3 out of 23 cell lines), both B2M alleles were disrupted because of homozygous deletions (8 samples), biallelic mutations (4 samples) and hemizygous deletions with inactivating mutation of the second allele (4 samples) ( Supplementary Fig. 4 and Supplementary Tables 12,13 ). Nine additional cases harbored monoallelic nonsense or frameshift mutations; however, the relatively low density of probe coverage for this small gene in the array may have prevented the identification of submicroscopic deletions in the second allele. Most mutations are predicted to generate truncated proteins as the result of premature stop codons (n = 3), splice site mutations (n = 2), out-of-frame indels (n = 6) or mutations at the translation-initiating methionine codon (n = 6); moreover, we found four missense mutations associated with inactivation of the second allele in four cases, as documented by sequencing analysis of cloned PCR products, suggesting that these mutations may also be functionally relevant (Supplementary Table 12) . Taken together, these lesions predict the loss of B2M expression, which is required for cell surface expression of HLA class I molecules and recognition by cytotoxic T lymphocytes 39 .
Focal homozygous deletions (n = 4, including one cell line), truncating mutations (n = 7, distributed in five cases and one cell line), in-frame deletions (n = 1) and hemizygous deletions (n = 10) were also recurrently detected in CD58, a member of the immunoglobulin superfamily that functions as a ligand of the CD2 protein on T and natural killer lymphocytes, participating in their adhesion and activation 40 ( Supplementary Fig. 4 and Supplementary Tables 14,15) . Although no copy number data were available to assess the status of the second allele in three of the mutated samples, and one case apparently retained a normal allele, the detection of frequent biallelic inactivation (n = 6 samples) suggests that CD58 may play a tumor suppressor function in DLBCL.
A new finding was the presence of focal deletions in TNFSF9, the gene encoding a transmembrane cytokine that belongs to the tumor necrosis factor ligand family (n = 10 out of 79 cases, of which three were homozygous) (Supplementary Table 16 ). TNFSF9 interacts with a costimulatory receptor molecule in T lymphocytes and follicular dendritic cells (TNFRSF9) and is involved in antigen presentation and in the generation of cytotoxic T cells 41 . Notably, Tnfsf9 knockout mice develop germinal center-derived lymphoma 42 .
Other lesions affecting regulators of immune responses include mutations and genomic deletions of CIITA, the major histocompatibility comples class II transactivator gene, as well as amplifications and breaks in the genes encoding the receptor immunomodulatory proteins PDL2 and PDL1, which often occur simultaneously (Supplementary Fig. 4a,d) . In PMBCL, rearrangements of CIITA have been recently shown to cause downregulation of surface HLA class II expression 19 , which is associated with reduced tumor cell immunogenicity, whereas amplifications of the PDL1 locus (also found in PMBCL and Hodgkin lymphoma) have been linked to impaired anti-tumor immune responses in several cancers 17, 18 . Although we Figure 6 Disruption of histone and/or chromatin modification genes is a major feature of DLBCL. (a) Mutation frequency of five genes encoding for histone-acetyltransferases and histonemethylation modifiers in GCB and ABC DLBCL (primary cases only). (b) dChipSNP heatmap showing median-smoothed log2 copy number ratio for DLBCL biopsies harboring KDM2B, MLL3 and MLL5 deletions or rearrangements; in the red-blue scale, white corresponds to a normal (diploid) copy number, blue is a deletion and red is a gain. Note that, because of the presence of non-tumor cells infiltrating the biopsies, the inferred copy number, and the corresponding color intensity, may vary across samples (supplementary table 11 ). The boxed area corresponds to the commonly deleted region, which is expanded below the heatmap to show the included genes. (c) Relationship between MLL2 mutations and mutations of genes encoding HATs. In the heatmap, rows correspond to the indicated genes and columns represent individual samples color coded according to the gene status (gray, unmutated; red, mutated or deleted). Of the three cases with MLL2 mutations showing simultaneous lesions at CREBBP, one harbored an amino acid substitution whose functional relevance is currently unclear. Thus, it is possible that this change represents a passenger event or a private germline variant not annotated in currently available databases; alternatively, these mutations may have milder effects, requiring additional cooperating lesions. (d) Overall fraction of DLBCL biopsies carrying mutations at one or more of the four histone-modification genes shown in c. A r t i c l e s observed no clear relationship between alterations at these five loci, their ability to interfere with the interaction between tumor cells and the microenvironment suggests that they may facilitate lymphomagenesis by allowing escape of immuno-surveillance mechanisms.
Alterations in pathways of post-germinal-center differentiation
Our results extend previous reports on the high frequency of genetic lesions affecting a variety of signaling pathways that share their ability to induce the NF-κB transcription complex, including the B-cell receptor, CD40 and Toll-like receptor pathways [13] [14] [15] [16] 43 . Overall, we found components of these pathways to be structurally altered in 63% (36 out of 59) of ABC and ~31% (12 out of 41) of GCB DLBCL biopsies (Supplementary Fig. 5a ), consistent with the observation that >90% of ABC DLBCLs and ~30% of GCB DLBCLs have nuclear NF-κB, which is direct evidence of its constitutive activation 13, 44 ; these alterations affect previously identified genes (for example, the negative regulator TNFAIP3 and the positive regulators CARD11, MYD88 and CD79B) but also newly discovered targets, such as ITPKB and TRAF3 ( Supplementary Fig. 5b,c) . In most cases, their largely mutually exclusive pattern of distribution ( Supplementary Fig. 5d ) implicates activation of NF-κB as a major downstream effect shared by the above lesions. Nonetheless, additional consequences may include deregulation of distinct signaling pathways, such as PI3K and MAPK (mutations of CD79B and CARD11) and/or JAK-STAT (mutations of MYD88) (Supplementary Fig. 5e ) 14, 16 . NF-κB alterations were frequently associated with a set of genetic lesions in downstream components of the signaling pathway that regulates germinal center exit and the generation of plasma cells, ultimately causing a block in terminal B-cell differentiation. Specifically, we confirmed the common biallelic loss of PRDM1 (also known as BLIMP1) in ABC DLBCL and its mutually exclusive relationship with chromosomal translocations of BCL6, which substitute its promoter region, making it constitutively active and resistant to IRF4-mediated suppression 45 (Supplementary Fig. 6 ). Because PRDM1 is a direct target of BCL6, these translocations will also result in the block of plasma cell differentiation (Supplementary Fig. 5e ). However, deregulation of BCL6 has broader consequences, including suppression of DNA damage responses by its direct targets (for example, p53 and p21) 46, 47 , which may be provided by other currently unknown lesions in the remaining cases.
Other transcription factors involved in B-cell differentiation emerged as common targets of various numerical or structural aberrations, including PAX5, IRF4, ETS1 (Supplementary Table 17 ) and MEF2B 48 , a gene highly expressed in the germinal center, that we found mutated in 8 out of 96 biopsies (Fig. 4 and Supplementary Table 18 ) and rearranged in one case (data not shown). Although the functional consequences of the above lesions remain to be defined, these findings indicate that, collectively, over half of all DLBCLs harbor defects at one or more genes involved in germinal center differentiation.
DISCUSSION
The main findings of this study are the initial elucidation of the complexity of the DLBCL coding genome and the discovery of a previously unidentified set of recurrent lesions that may be of relevance for the understanding of the pathogenesis of this malignancy.
The combined set of mutations and copy number alterations detected in the six DLBCL discovery cases does not allow a final assessment of the precise number of genomic alterations affecting coding genes but does provide information about the order of magnitude of the lesions associated with this malignancy. The estimate of >30 alterations per case emerging from this study reflects only those events with abundant to complete clonal representation, that is, changes that were likely present during the initial phases of tumor expansion and thus promoted malignant transformation. Furthermore, this estimate does not include an additional 40% of mutations that may have been missed by the WES approach because of the relatively low depth of coverage (Online Methods) as well as chromosomal translocations other than those affecting BCL6, BCL2 and MYC (which are not detectable by the two methodologies used). Thus, it can be concluded that the coding genome of DLBCL contains <100 lesions on average. Although very approximate, this figure is informative for future studies and may serve as an initial database for the determination of recurrence in additional panels of cases.
When compared to other malignancies, the order of magnitude of lesions detected in DLBCL appears lower than that reported for certain epithelial cancers 49, 50 . Among hematologic malignancies, the complexity of the DLBCL genome is not markedly different from multiple myeloma 51 , whereas it appears much more complex than acute myeloid leukemia [52] [53] [54] and chronic lymphocytic leukemia 23, 27 in terms of both copy number alterations and mutational load. On the other hand, the observed predominance of transitions over transversions, the preferential targeting of C/G and G/C base pairs and the significant bias toward alterations at CpG dinucleotides is emerging as a common feature shared by most malignancies studied so far, including those of epithelial derivation. This pattern of alterations is generally derived from endogenous biochemical processes such as the spontaneous deamination of 5-methylcytosine residues. However, it cannot be excluded that the abnormal and/or ectopic activity of activation-induced cytidine deaminase has a role in the generation of DNA lesions affecting these residues; indeed, activationinduced cytidine deaminase has been shown to target the 5′ portion of multiple genes-mostly noncoding-in DLBCL, and some of the mutations detected in this study may in fact reflect the activity of aberrant somatic hypermutation (for example, PIM1) 55 .
Among the vast array of genetic lesions identified in the DLBCL genome, alterations of MLL family members, and in particular MLL2, appear especially frequent. MLL2 encodes a trimethyltransferase residing in a complex with well-documented influence on the expression of a large number of genes. The pattern of monoallelic somatic inactivation observed in DLBCL suggests a role for MLL2 as a haploinsufficient tumor suppressor, consistent with the observation that monoallelic MLL2 truncating mutations leading to decreased gene dosage have a pathogenic effect in Kabuki syndrome, a congenital disorder characterized by developmental and intellectual abnormalities 56 . A role for MLL genes in malignant transformation is supported by the involvement of MLL in the pathogenesis of acute leukemia 57 , although by a distinct and partially unclear mechanism, and by the recent finding of somatic inactivating mutations in both MLL2 and MLL3 in various cancers 26, 51, 58 . Collectively, alterations of chromatinmodifying enzymes, including HMTs and HATs, emerge as the most frequent alterations associated with DLBCL pathogenesis, being present in over one third of cases, independent of disease subtype (~50% in GCB DLBC and ~30% in ABC DLBCL).
A second new finding in the DLBCL coding genome is the high frequency of alterations in genes that are involved in immune recognition by T cells. In particular, the observation that biallelic inactivation of B2M is more common than originally implicated based on only a few samples analyzed 59 suggests a major role for these lesions in causing the loss of HLA class I expression, which constitutes a frequent event in DLBCL 60 . The findings herein provide a mechanistic explanation for a fraction of these cases and suggest the existence of additional A r t i c l e s genetic or epigenetic mechanisms preventing the expression of HLA class I molecules. Because it is well established that the lack of these molecules makes cells insensitive to cytotoxic T-cell-mediated killing, loss of B2M may represent a major mechanism of tumor escape from immune surveillance.
The distribution of recurrent lesions among DLBCL subtypes defined by cell of origin supports the existence of both common and subtype-specific genetic lesions. The former are represented by the inactivating chromatin-modifying functions, including genes encoding HAT and HMT, as well as the newly discovered alterations of immune recognition functions. These alterations may represent common pathways necessary for the development of the DLBCL phenotype independent of cell of origin. Conversely, our results confirm the preferential association of BCL2 and MYC alterations with GCB DLBCL 7 and of alterations in the NF-κB and BCL6-BLIMP1 axis with ABC DLBCL 10 . The observed distribution has immediate clinical implications, as it suggests the development of therapies that combine drugs targeting commonly altered pathways with those targeting pathways selectively disrupted in DLBCL subtypes.
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samples. Alterations present in the pool of reference samples were presumed to be inherited and therefore were eliminated. In addition, CNVs were excluded if the same regions were present in the Database of Genomic Variants (see URLs). Adjacent regions separated by <8 markers and/or by germline CNVs were considered to be part of the same aberration if they showed comparable probe intensity values. Genes (within the RefSeq database) were considered to be affected by deletions if one or more of their exons were encompassed by the aberration. The following linear thresholds were used to annotate copy number aberrations, which take into account the presence of contaminating normal cells in the biopsies: heterozygous deletion, ≤1.75; homozygous deletion, ≤0.95; copy number gain, ≥2.3; and gene amplification, ≥4. Additionally, the presence of both copy number gains and copy number losses affecting distinct subsets of exons within a given gene in the same tumor sample was annotated as a breakpoint, as this pattern could reflect an unbalanced rearrangement or a rearrangement with loss of the reciprocal translocation partner.
